Ms Renne Nyarko (middle), Mr Vishaal Mohan (right), Chief Marketing Officer of Luex, and other senior delegates of the company with the award after the ceremony

Luex Healthcare wins 2021 Multinational Company of the Year

Daily Graphic Sep - 14 - 2021 , 06:47 2 minutes read

Luex Healthcare has been awarded the Multinational Company (MNC) of the year at the third edition of the Ghana Pharma Awards 2021 held at the Kempinski Gold Coast Hotel in Accra.

The award, endorsed the outstanding contribution of Luex to the development of the pharmaceutical industry in Ghana and Africa as a whole.

Luex is a UK-based healthcare company operating in the field of pharmaceutical manufacturing, logistics, distribution and marketing since 1987.

It is directly and indirectly present in over 20 countries and has over 15 manufacturing partnerships with mostly the World Health Organisation Good Manufacturing Practices (WHO-c GMP) sites of high standards of quality compliance, including Unichem Industries, located in Ghana.

Dedication

The Chief Marketing Officer of Luex, Mr Vishaal Mohan, who picked up the award on behalf of the group, commended the medical fraternity in Ghana.

“We dedicate this award to the compassionate and dedicated healthcare professionals and partners who have helped us over the years to deliver trusted & valued medicines throughout Ghana and beyond,” he stated.

He pledged that Luex would commence the manufacturing of some of its liquids & ointments in Ghana this year to ensure affordability and accessibility for all in the years to come.

Luex

“Over the past three decades, Luex has become a trusted name across the medical fraternity in Ghana with over 100 key brands across all major therapeutic categories.

“The company has equally strengthened its over the counter range, which has led to Luex becoming a household name nationwide,” Mr Mohan said.

He hinted that the company had also undertaken trials and studies on some key ethical products locally unlike other multinational companies which brought in studies conducted abroad.

Mr Mohan acknowledged that undertaking trials in developing countries such as Ghana were more complex, “but this research can be a solution to the high rates of early mortality.”

He said the company’s product “Mycolex cream and powder” were also recently endorsed by the Ghana Society of Dermatology as an antifungal agent of choice.